Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. Int J Mol Sci 2018 Jun 14;19(6)
Date
06/15/2018Pubmed ID
29899215Pubmed Central ID
PMC6032212DOI
10.3390/ijms19061765Scopus ID
2-s2.0-85048688002 (requires institutional sign-in at Scopus site) 45 CitationsAbstract
Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. With its overall dismal prognosis (the median survival is 14 months), GBMs demonstrate a resounding resilience against all current treatment modalities. The absence of a major progress in the treatment of GBM maybe a result of our poor understanding of both GBM tumor biology and the mechanisms underlying the acquirement of treatment resistance in recurrent GBMs. A comprehensive understanding of these markers is mandatory for the development of treatments against therapy-resistant GBMs. This review also provides an overview of a novel marker called acid ceramidase and its implication in the development of radioresistant GBMs. Multiple signaling pathways were found altered in radioresistant GBMs. Given these global alterations of multiple signaling pathways found in radioresistant GBMs, an effective treatment for radioresistant GBMs may require a cocktail containing multiple agents targeting multiple cancer-inducing pathways in order to have a chance to make a substantial impact on improving the overall GBM survival.
Author List
Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan NAuthor
Saman Shabani MD Assistant Professor in the Neurosurgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBiomarkers, Tumor
Brain Neoplasms
Drug Resistance, Neoplasm
Glioblastoma
Humans
Radiation Tolerance
